4.2 Illicit Drug & Cannabis Counseling

ABFM Family Medicine Certification Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Structure, Blueprint & Clinical Decision-Making

1.1 Exam Blueprint, FMCLA vs. One-Day Exam & Board Scoring 1.2 Clinical Reasoning, Test-Taking Strategy & Ambiguity Management 1.3 Evidence-Based Medicine & Clinical Practice Guidelines in Primary Care

2 Chapter 2: Healthcare Systems, Practice Management & Quality

2.1 Practice Management, Billing, Coding & Documentation 2.2 Quality Improvement, Patient Safety & Diagnostic Stewardship 2.3 Interprofessional Team-Based Care & Care Coordination

3 Chapter 3: Ethics, Law, Biostatistics & Health Equity

3.1 Medical Ethics, Informed Consent & Surrogate Decision-Making 3.2 Biostatistics, Clinical Epidemiology & Diagnostic Test Interpretation 3.3 Social Determinants of Health, Health Equity & Cultural Humility 3.4 Physician Wellness, Burnout Prevention & Professionalism

4 Chapter 4: Lifestyle Counseling & Behavior Change

4.1 Alcohol Use Screening & Brief Intervention 4.2 Illicit Drug & Cannabis Counseling 4.3 Tobacco & Vaping Cessation Counseling

5 Chapter 5: Nutrition, Physical Activity & Chronic Disease Prevention

5.1 Dietary Counseling for Obesity & Chronic Disease Prevention 5.2 Exercise Prescription & Physical Activity Counseling 5.3 Genetic Risk Assessment & Family History Counseling

6 Chapter 6: Routine Adult Immunizations

6.1 ACIP Adult Respiratory Vaccines: Influenza, COVID-19, RSV & Pneumococcal 6.2 ACIP Adult Non-Respiratory Vaccines: Tdap, Shingrix, HPV & Hep B 6.3 Immunizations in Special Populations: Pregnancy, Asplenia & Immunocompromise

7 Chapter 7: Pediatric Health Maintenance & Surveillance

7.1 Newborn Examination & Early Postnatal Care 7.2 Well-Child Care, Developmental Surveillance & Milestones 7.3 Pediatric & Adolescent Screening: Vision, Hearing, Anemia & Lead 7.4 Pediatric Oral Health, Dental Screening & Fluoride

8 Chapter 8: Behavioral Health & Safety Screening

8.1 Primary Care Depression, Anxiety & Behavioral Health Screening 8.2 Domestic Violence, Intimate Partner Violence & Firearm Safety 8.3 Occupational Health & Recreational Safety Counseling

9 Chapter 9: Adult Preventive Screening: Cardiovascular & Metabolic

9.1 Cardiovascular Disease & Hypertension Screening 9.2 Type 2 Diabetes Screening & Prediabetes Risk Stratification 9.3 Abdominal Aortic Aneurysm & Osteoporosis Screening

10 Chapter 10: Adult Cancer Screening: Breast & Gynecologic

10.1 Breast Cancer Screening & Risk-Assessment 10.2 Cervical Cancer Screening & ASCCP Algorithms 10.3 Skin Cancer Clinical Assessment & Counseling

11 Chapter 11: Adult Cancer Screening: Colorectal, Lung & Prostate

11.1 Colorectal Cancer Screening Modalities & Intervals 11.2 Lung Cancer Screening with Low-Dose CT 11.3 Prostate Cancer Screening & Shared Decision-Making

12 Chapter 12: Sexual Health, Infectious Disease Screening & Contraception

12.1 Sexual Health Counseling & Risk-Reduction Strategies 12.2 STI Screening: Chlamydia, Gonorrhea, Syphilis & Trichomoniasis 12.3 Bloodborne Infectious Disease Screening: HIV & Hepatitis C

13 Chapter 13: Reproductive Life Planning, Lactation & Preoperative Care

13.1 Preconception Planning & Comprehensive Contraception Management 13.2 Lactation Support & Breastfeeding Counseling 13.3 Preoperative Medical Evaluation & Pre-Participation Sports Exam

14 Chapter 14: Emergent Cardiovascular Conditions

14.1 Acute Coronary Syndromes & Myocardial Infarction 14.2 Acute Chest Pain Risk Stratification & Triage 14.3 Acute or Critical Valvular Heart Emergencies

15 Chapter 15: Cardiac Arrhythmias, Heart Failure & Hypertensive Crises

15.1 Acute Atrial & Ventricular Arrhythmias 15.2 Acute Decompensated Heart Failure & Cardiogenic Shock 15.3 Hypertensive Emergency & Urgency Management

16 Chapter 16: Vascular & Thromboembolic Emergencies

16.1 Pulmonary Embolism & Deep Vein Thrombosis 16.2 Acute Aortic Syndromes & Peripheral Vascular Emergencies 16.3 Critical Limb Ischemia & Acute Arterial Occlusion

17 Chapter 17: Neurologic Emergencies: Stroke & Altered Consciousness

17.1 Acute Ischemic Stroke & Intracranial Hemorrhage 17.2 Syncope Evaluation & Status Epilepticus 17.3 Acute Delirium, Encephalopathy & Severe Confusion

18 Chapter 18: Neurologic Trauma & Acute Cranial Emergencies

18.1 Concussion, Moderate-to-Severe TBI & Intracranial Injury 18.2 Thunderclap & Acute Severe Secondary Headaches 18.3 Acute Ophthalmologic Emergencies

19 Chapter 19: Acute Abdominal, Pelvic & Gastrointestinal Emergencies

19.1 Acute Abdominal & Pelvic Pain Triage 19.2 Upper & Lower Gastrointestinal Bleeding 19.3 Acute Hepatic Failure, Cholangitis & Severe Jaundice

20 Chapter 20: Acute Pulmonary & Airway Emergencies

20.1 Acute Hypoxic Respiratory Failure & ARDS 20.2 Severe Community-Acquired Pneumonia & Empyema 20.3 Acute Severe Epistaxis & Airway Obstruction

21 Chapter 21: Acute Traumatic Injuries & Wound Care

21.1 Major Trauma Resuscitation & Initial Assessment 21.2 Burn Assessment, Inhalation Injury & Resuscitation 21.3 Laceration Management, Complex Wounds & Animal Bites

22 Chapter 22: Acute Orthopedic & Musculoskeletal Emergencies

22.1 Acute Ambulatory Fractures & Initial Splinting 22.2 Compartment Syndrome & Major Orthopedic Trauma 22.3 Septic Arthritis & Acute Microcrystalline Crises

23 Chapter 23: Severe Infections, Sepsis & Systemic Emergencies

23.1 Sepsis, Septic Shock & Initial Fluid Resuscitation 23.2 Necrotizing Soft Tissue Infections & Severe CNS Infections 23.3 Anaphylaxis Diagnosis, Epinephrine Dosing & Airway Protection

24 Chapter 24: Metabolic, Endocrine & Electrolyte Emergencies

24.1 Diabetic Ketoacidosis & Hyperosmolar Hyperglycemic State 24.2 Critical Electrolyte Emergencies: Dyskalemias & Dysnatremias 24.3 Severe Calcium Abnormalities & Acute Adrenal Crisis

25 Chapter 25: Hematologic, Urologic & Dental Emergencies

25.1 Severe Symptomatic Anemias & Coagulopathic Emergencies 25.2 Testicular Torsion, Priapism & Acute Urinary Retention 25.3 Urgent Odontogenic Infections & Dental Trauma

26 Chapter 26: Psychiatric, Behavioral & Obstetric/Gynecologic Emergencies

26.1 Suicidal Ideation, Acute Agitation & Behavioral Emergencies 26.2 Acute Physical & Sexual Assault Care 26.3 Life-Threatening Vaginal Bleeding & Ectopic Pregnancy 26.4 Environmental Heat Stroke & Severe Hypothermia

27 Chapter 27: Acute Head, Neck & Neurologic Symptoms

27.1 Primary Acute Headaches: Migraine, Tension & Cluster 27.2 Concussion & Minor Closed Head Injury Evaluation 27.3 Transient Ischemic Attack Evaluation & ABCD2 Risk Scoring

28 Chapter 28: Acute Cranial Nerves, Hearing & Sensory Symptoms

28.1 Peripheral Neuropathies: Bell's Palsy, Carpal Tunnel & Radiculopathy 28.2 Acute Tinnitus, Sudden Sensorineural Hearing Loss & Cerumen Impaction 28.3 Acute Dizziness, Benign Paroxysmal Positional Vertigo & Vestibular Neuritis

29 Chapter 29: Acute Upper Respiratory Tract Infections

29.1 Acute Viral Rhinosinusitis vs. Bacterial Rhinosinusitis 29.2 Acute Pharyngitis: Group A Streptococcus & Centor Criteria 29.3 Acute Otitis Media, Otitis Externa & Serous Effusion

30 Chapter 30: Acute Lower Respiratory Infections & Cough

30.1 Influenza, COVID-19 & Viral Respiratory Syndromes 30.2 Acute Bronchitis & Lower Respiratory Tract Infections 30.3 Ambulatory Community-Acquired Pneumonia

31 Chapter 31: Allergic, Nasal & Non-Infectious Pulmonary Conditions

31.1 Allergic Rhinitis & Acute Non-Anaphylactic Allergic Reactions 31.2 Acute Dyspnea in Ambulatory Care 31.3 Interstitial Lung Diseases & Sarcoidosis Presentation

32 Chapter 32: Acute Chest, Cardiac & Vascular Symptoms

32.1 Palpitations Evaluation & Arrhythmia Triage in Primary Care 32.2 Deep Vein Thrombosis & Superficial Thrombophlebitis 32.3 Ambulatory Hypotension & Orthostasis Evaluation

33 Chapter 33: Acute Upper Gastrointestinal Conditions

33.1 Peptic Ulcer Disease & Gastritis 33.2 Dysphagia, Esophagitis & Acute Esophageal Disorders 33.3 Acute Nausea, Vomiting & Foodborne Illness

34 Chapter 34: Acute Lower Gastrointestinal Conditions

34.1 Acute Infectious Diarrhea & Gastroenteritis 34.2 Acute Constipation & Functional Bowel Changes 34.3 Ano-Rectal Disorders: Hemorrhoids, Fissures, Abscesses & Pruritus Ani

35 Chapter 35: Inflammatory, Functional & Malabsorptive GI Disorders

35.1 Acute Flares of Inflammatory Bowel Disease 35.2 Irritable Bowel Syndrome: Diagnosis, Subtyping & Management 35.3 Celiac Disease & Malabsorption Syndromes

36 Chapter 36: Acute Abdominal, Hepatic & Biliary Disorders

36.1 Ambulatory Abdominal & Pelvic Pain Triage 36.2 Acute Cholecystitis, Biliary Colic & Pancreatitis 36.3 Acute Liver Injury & Viral Hepatitis

37 Chapter 37: Acute Abdominal Wall, Hernias & Dental Conditions

37.1 Abdominal Wall, Inguinal & Ventral Hernias 37.2 Acute Dental Pain, Odontogenic Abscess & Aphthous Ulcers 37.3 Acute Edema: Unilateral vs. Bilateral Diagnostic Evaluation

38 Chapter 38: Acute Infectious Dermatoses

38.1 Bacterial Skin Infections: Impetigo, Cellulitis & Cutaneous Abscesses 38.2 Fungal Skin Infections: Tinea Corporis, Cruris, Pedis & Onychomycosis 38.3 Viral Cutaneous Infections: Herpes Simplex, Zoster & Molluscum Contagiosum

39 Chapter 39: Inflammatory, Allergic & Autoimmune Dermatoses

39.1 Atopic Dermatitis, Contact Dermatitis & Eczematous Flares 39.2 Non-Infectious Rashes: Urticaria, Drug Eruptions & Erythema Multiforme 39.3 Cutaneous Malignancies & Premalignant Lesions: AK, BCC, SCC & Melanoma

40 Chapter 40: Acute Shoulder, Elbow & Upper Extremity Injuries

40.1 Rotator Cuff Pathology, Tendinopathy & Shoulder Impingement 40.2 Lateral & Medial Epicondylitis, Olecranon Bursitis & Elbow Sprains 40.3 Wrist & Hand Soft-Tissue Injuries: De Quervain, TFCC & Finger Sprains

41 Chapter 41: Acute Knee, Ankle & Lower Extremity Injuries

41.1 Meniscal Tears, Ligamentous Knee Injuries & Patellofemoral Pain 41.2 Ankle Sprains, Ottawa Ankle Rules & Achilles Tendinopathy 41.3 Plantar Fasciitis, Shin Splints & Overuse Syndromes

42 Chapter 42: Acute Ambulatory Fractures & Dislocations

42.1 Distal Radius, Scaphoid & Common Upper Extremity Fractures 42.2 Metatarsal, Clavicle & Common Lower Extremity Fractures 42.3 Joint Dislocation Management: Nursemaid's Elbow & Shoulder Subluxation

43 Chapter 43: Acute Axial Musculoskeletal Pain & Falls

43.1 Acute Low Back Pain: Red Flags, Strain & Disc Herniation 43.2 Acute Cervical Strain, Whiplash & Axial Neck Pain 43.3 Evaluation of Falls in Ambulatory & Older Patients

44 Chapter 44: Acute Inflammatory Arthropathies & Generalized Pain

44.1 Acute Inflammatory Arthritis & Spondyloarthropathies 44.2 Myalgias, Rhabdomyolysis & Post-Viral Pain Syndromes 44.3 Acute Non-Headache Pain Management Strategies

45 Chapter 45: Acute Renal, Urinary & Genitourinary Conditions

45.1 Uncomplicated UTI, Pyelonephritis & Acute Urethritis 45.2 Hematuria Workup & Glomerulonephritis 45.3 Nephrolithiasis & Acute Urinary Tract Obstruction

46 Chapter 46: Acute Male Genitourinary & Prostatic Conditions

46.1 Acute Prostatitis, Epididymitis & Orchitis 46.2 Acute Scrotal Pain: Torsion vs Appendage, BPH & Male Genital Emergencies 46.3 Acute Urinary Retention & Incontinence Evaluation

47 Chapter 47: Acute Women's Health & Early Pregnancy Care

47.1 Early Pregnancy Diagnosis, Dating & Initial Complications 47.2 Abnormal Uterine Bleeding & Acute Menstrual Disorders 47.3 Premenstrual Syndrome & Premenstrual Dysphoric Disorder

48 Chapter 48: Breast Disorders, STIs & Pediatric Elimination

48.1 Palpable Breast Mass, Mastitis & Nipple Discharge 48.2 Sexually Transmitted Infections: Diagnosis, Staging & CDC Guidelines 48.3 Pediatric Enuresis & Encopresis

49 Chapter 49: Systemic Signs, Metabolic Dysregulation & Miscellaneous Infections

49.1 Acute Fever, Sepsis Screening & FUO in Primary Care 49.2 Acute Hyperglycemia & Symptomatic Hypoglycemia 49.3 Electrolyte Abnormalities: Mild-to-Moderate Disturbances 49.4 Vector-Borne, Tick-Borne & Rickettsial Illnesses

50 Chapter 50: Chronic Cardiovascular Diseases: Hypertension & Ischemia

50.1 Essential Hypertension Management: 2025 AHA/ACC Guideline & JNC Strategies 50.2 Chronic Coronary Artery Disease & Post-MI Secondary Prevention 50.3 Chronic Heart Failure: HFrEF, HFpEF & Quadruple GDMT

51 Chapter 51: Chronic Vascular, Valvular & Dyslipidemic Diseases

51.1 Peripheral Arterial Disease & Claudication 51.2 Chronic Valvular Heart Disease & Murmur Evaluation 51.3 Lipid Disorders & ASCVD Risk-Based Statin Therapy

52 Chapter 52: Chronic Respiratory Diseases: Asthma & COPD

52.1 Chronic Asthma Management: GINA Stepwise SMART Therapy 52.2 Chronic Obstructive Pulmonary Disease: GOLD Recommendations 52.3 Solitary Pulmonary Nodule Evaluation & Fleischner Society Criteria

53 Chapter 53: Chronic Metabolic Diseases: Diabetes Mellitus

53.1 Type 2 Diabetes Management: ADA Pharmacotherapy Algorithms 53.2 Type 1 Diabetes: Basal-Bolus Insulin, CGMs & Diabetic Complications 53.3 Diabetic Microvascular & Macrovascular Disease Surveillance

54 Chapter 54: Obesity, Nutrition & Metabolic Bone Diseases

54.1 Medical & Behavioral Management of Obesity & Incretin Mimetics 54.2 Osteoporosis & Metabolic Bone Disease: DEXA, FRAX & Antiresorptives 54.3 Nutritional Deficiencies: Vitamin D, B12, Iron & Malnutrition

55 Chapter 55: Chronic Endocrine Disorders

55.1 Primary & Subclinical Hypothyroidism, Hyperthyroidism & Nodules 55.2 Adrenal Disorders: Addison's Disease & Cushing's Syndrome 55.3 Hypercalcemia, Hyperparathyroidism & Pituitary Disorders

56 Chapter 56: Chronic Kidney Disease & Venous Disorders

56.1 Chronic Kidney Disease: KDIGO Staging & Renoprotective Therapy 56.2 Chronic Venous Insufficiency, Stasis Dermatitis & Lymphedema 56.3 Chronic Electrolyte & Acid-Base Management in CKD

57 Chapter 57: Chronic Gastrointestinal & Hepatic Diseases

57.1 Gastroesophageal Reflux Disease, Barrett's Esophagus & Dyspepsia 57.2 Chronic Liver Disease: MASLD/NAFLD, Cirrhosis & Portal Hypertension 57.3 Viral Hepatitis B & C: Long-Term Monitoring & DAA Therapy

58 Chapter 58: Colorectal Surveillance & Chronic Pancreaticobiliary Care

58.1 Post-Polypectomy Colorectal Polyp Surveillance Guidelines 58.2 Chronic Pancreatitis & Exocrine Pancreatic Insufficiency 58.3 Chronic Nausea, Gastroparesis & Functional GI Disorders

59 Chapter 59: Chronic Musculoskeletal & Rheumatologic Disorders

59.1 Osteoarthritis: Hip, Knee & Hand Management 59.2 Spinal Conditions: Spinal Stenosis, Spondylolisthesis & Compression Fractures 59.3 Chronic Myopathies & Fibromyalgia Syndrome

60 Chapter 60: Chronic Neurologic & Neurodegenerative Disorders

60.1 Dementia: Alzheimer's, Vascular & Lewy Body Disease 60.2 Parkinson's Disease & Essential Tremor 60.3 Epilepsy: Chronic Antiseizure Medications & Post-Stroke Care

61 Chapter 61: Chronic Peripheral Nerves, Pain & Sensory Disorders

61.1 Diabetic & Chronic Peripheral Neuropathies 61.2 Chronic Pain Syndromes & Chronic Daily Headaches 61.3 Chronic Tinnitus, Presbycusis & Persistent Dizziness

62 Chapter 62: Chronic Psychiatric Disorders

62.1 Major Depressive Disorder & Generalized Anxiety Disorder 62.2 Bipolar Disorder: Maintenance Pharmacotherapy & Lithium Monitoring 62.3 Adult & Pediatric Attention-Deficit/Hyperactivity Disorder

63 Chapter 63: Chronic Behavioral Health & Neurodevelopmental Conditions

63.1 Chronic Behavioral Conditions: PTSD, OCD & Somatization 63.2 Autism Spectrum Disorder & Intellectual Disabilities 63.3 Eating Disorders: Anorexia Nervosa, Bulimia & Binge Eating

64 Chapter 64: Chronic Substance Use Disorders & Tobacco Cessation

64.1 Alcohol Use Disorder: Pharmacotherapy & Relapse Prevention 64.2 Opioid & Stimulant Use Disorders: MOUD & Harm Reduction 64.3 Longitudinal Tobacco Cessation Pharmacotherapy

65 Chapter 65: Chronic Dermatologic Conditions

65.1 Acne Vulgaris, Rosacea & Seborrheic Dermatitis 65.2 Chronic Plaque Psoriasis & Biologic Therapies 65.3 Chronic Eczema, Hidradenitis Suppurativa & Cutaneous Lupus

66 Chapter 66: Chronic Reproductive, Infectious & Geriatric Special Care

66.1 Chronic Menstrual Disorders, Infertility & Sexual Dysfunction 66.2 Menopause Management & Hormone Replacement Therapy 66.3 Chronic HIV Infection Management & Primary Care Integration 66.4 Gender-Affirming Primary Care & Hormone Therapy 66.5 Advance Care Planning, Palliative Care & End-of-Life Symptom Control

67 Chapter 67: Continuity Care: Sleep, Fatigue, Cancer, Pregnancy & the Adult Preventive Visit

67.1 Chronic Insomnia & Obstructive Sleep Apnea 67.2 Chronic Malaise, Fatigue & ME/CFS 67.3 Primary Care During Cancer Treatment & Survivorship 67.4 Routine Prenatal Care & Longitudinal Pregnancy Management 67.5 The Periodic Adult Health Examination & Medicare Annual Wellness Visit

4.2 Illicit Drug & Cannabis Counseling

Key Takeaways Explain This Topic AI

The USPSTF recommends screening for illicit drug use in all adults aged 18 and older (Grade B) using validated questionnaires (e.g., DAST-10, ASSIST, NIDA Quick Screen) whenever services for accurate diagnosis, effective treatment, and appropriate care can be provided or linked.

Cannabis Use Disorder (CUD) affects approximately 30% of regular users, exacerbated by modern commercial products with THC concentrations exceeding 20-30% in flower and up to 90% in concentrates, leading to tolerance, withdrawal syndrome, and doubled psychosis risk in vulnerable youth.

Cannabinoid Hyperemesis Syndrome (CHS) presents in chronic daily cannabis users as cyclical intractable nausea, severe colicky abdominal pain, and intractable vomiting with pathognomonic relief from compulsive hot water bathing; acute first-line treatment consists of topical capsaicin 0.025%-0.075% cream and dopamine D2 antagonists (haloperidol), while definitive cure mandates total cannabinoid cessation.

Stimulant use (cocaine, methamphetamine) precipitates severe cardiovascular crises, including coronary vasospasm, myocardial infarction, accelerated atherosclerosis, and dilated cardiomyopathy; pure beta-blocker monotherapy should be avoided in acute cocaine toxicity due to unopposed alpha-adrenergic vasoconstriction, while chronic use frequently results in rampant 'meth mouth' caries.

Harm reduction is an evidence-based standard of care: clinicians should coprescribe intranasal naloxone (4 mg) to all individuals with substance use disorders or high-dose opioid therapy (>=50 MME/day), distribute fentanyl test strips (FTS), and refer to Syringe Service Programs (SSPs) to reduce HIV and viral hepatitis transmission by over 50%.

Last updated: September 2026

Screening for Illicit Drug Use in Primary Care

Substance use disorders represent a major public health crisis in primary care, intersecting with infectious disease transmission, mental health comorbidities, chronic pain management, and preventable overdose mortality. The U.S. Preventive Services Task Force (USPSTF) issues a Grade B recommendation that clinicians screen for illicit drug use in adults aged 18 and older, including pregnant and postpartum individuals, provided that services for accurate diagnosis, effective treatment, and appropriate care can be offered or linked.

Screening must encompass non-medical use of prescription medications (opioids, sedatives, stimulants) as well as illicit drugs (cannabis, cocaine, methamphetamine, heroin, illicit fentanyl, synthetic cannabinoids, MDMA, hallucinogens). Universal screening normalizes the clinical inquiry, decreases stigma, and prevents biased profiling.

Validated Screening Instruments

NIDA Single-Item Screener : "How many times in the past year have you used an illegal drug or used a prescription medication for nonmedical reasons?" (A response of ≥ 1 \ge 1 ≥ 1 is positive; sensitivity ~100%, specificity ~74%).

DAST-10 (Drug Abuse Screening Test) : A 10-item self-administered or clinician-administered tool evaluating substance-related problems (excluding alcohol and tobacco). Scored 0 to 10:

Score 0 : None (reinforce healthy behaviors; rescreen annually).

Score 1–2 : Low risk (provide brief motivational feedback and monitoring).

Score 3–5 : Moderate risk (conduct full clinical assessment; deliver brief intervention; consider referral).

Score 6–8 : Substantial risk (conduct intensive assessment; refer to specialized outpatient or residential addiction treatment).

Score 9–10 : Severe risk (urgent referral to specialized addiction medicine, medical detoxification, or inpatient care).

WHO ASSIST (Alcohol, Smoking and Substance Involvement Screening Test) : An 8-item comprehensive tool developed by the World Health Organization that calculates a substance-specific involvement score for 10 substance classes, categorizing risk as low, moderate, or high to guide clinical action.

Cannabis: Pharmacokinetics, Potency Trends & Cannabis Use Disorder

Cannabis is the most widely used psychoactive substance in the United States after alcohol and nicotine. The legal and commercial landscape has evolved rapidly, accompanied by dramatic increases in product potency that have fundamentally altered clinical presentations.

Modern Potency Trends & Pharmacokinetics

Surging Delta-9-THC Concentrations : In the 1990s, typical seized cannabis flower contained 3% to 4% delta-9-tetrahydrocannabinol (THC). Contemporary commercially available flower routinely averages 15% to 30% THC , while concentrated extracts ("dabs", wax, shatter, vape cartridges) frequently contain 70% to 90%+ THC .

Pharmacokinetics : Inhalation yields rapid alveolar absorption, with peak plasma concentrations within 10 to 30 minutes and clinical effects lasting 2 to 4 hours. Oral ingestion (edibles) undergoes variable, delayed gastrointestinal absorption and extensive hepatic first-pass metabolism to 11-hydroxy-THC (a potent psychoactive metabolite), with onset delayed by 30 to 120 minutes and duration extending 6 to 12 hours. This delay frequently prompts users to ingest repeated doses, precipitating acute intoxication, panic attacks, and toxic delirium.

Cannabis Use Disorder (CUD)

Approximately 30% of regular cannabis users develop Cannabis Use Disorder. DSM-5-TR defines CUD by the same 11 criteria as other substance use disorders (impaired control, social impairment, risky use, tolerance, and withdrawal). Severity is classified as Mild (2–3 criteria), Moderate (4–5 criteria), or Severe (6+ criteria).

Cannabis Withdrawal Syndrome

Cannabis withdrawal occurs in up to 50% of daily or near-daily users following abrupt cessation. Symptoms typically emerge within 24 to 72 hours , peak at days 2 to 6 , and persist for 1 to 3 weeks :

Psychological Symptoms : Marked irritability, anger, aggression, nervousness, anxiety, depressed mood, restlessness.

Sleep Disturbances : Severe insomnia, vivid and bizarre dreams, nightmares.

Physical Symptoms : Decreased appetite and significant weight loss, abdominal pain, shakiness/tremors, sweating, fever, chills, headache.

Clinical Reassurance : Patients frequently attribute withdrawal symptoms to "rebound baseline anxiety" and resume cannabis; clinicians must educate patients that these neuroadaptive symptoms are transient.

Cannabinoid Hyperemesis Syndrome (CHS)

Cannabinoid Hyperemesis Syndrome is a distinct clinical entity occurring in individuals with chronic, high-dose cannabis exposure (typically daily use for > 1 >1 > 1 to 2 years).

Clinical Presentation & Diagnostic Triad

Severe, Cyclical Nausea and Intractable Vomiting : Recurrent episodes of colicky, periumbilical or epigastric abdominal pain accompanied by profuse non-bloody emesis occurring multiple times per hour, often leading to severe volume depletion, prerenal acute kidney injury, and electrolyte collapse (hypokalemia, hypochloremic metabolic alkalosis).

History of Chronic, Heavy Cannabis Consumption : Typically daily or near-daily consumption of high-potency cannabis products.

Compulsive Hot Water Bathing or Showering : A pathognomonic behavioral hallmark where patients spend hours submerged in scalding hot showers or baths, which provides transient, dramatic relief of nausea and abdominal pain.

Pathophysiology

The Paradoxical Effect : Acute low-dose THC stimulates CB1 receptors in the dorsal vagal complex, producing antiemetic effects. However, chronic excessive exposure to high concentrations of THC down-regulates and desensitizes peripheral enteric CB1 receptors, leading to gastric hypomotility, delayed gastric emptying, and splanchnic vasodilation.

TRPV1 Receptor Dysregulation : THC also binds and down-regulates Transient Receptor Potential Vanilloid-1 (TRPV1) receptors in the nodose ganglion and hypothalamus (the thermoregulatory center). Scalding hot water activates cutaneous TRPV1 receptors, restoring hypothalamic temperature homeostasis and diverting splanchnic blood flow to cutaneous beds ("cutaneous steal syndrome"), thereby relieving visceral pain and vomiting.

Acute Pharmacotherapy & Management

Ineffective Standard Antiemetics : Conventional antiemetics—including ondansetron (5-HT3 antagonist), promethazine, metoclopramide, and prochlorperazine—are notoriously ineffective in CHS and frequently fail to abort symptoms.

Topical Capsaicin Cream (0.025% to 0.075%) : Highly effective first-line acute therapy. Applied as a thin film to the abdomen, back, or arms, capsaicin acts as a potent TRPV1 receptor agonist, mimicking the neurochemical relief of a hot shower. Wash hands thoroughly after application; avoid mucous membranes.

Dopamine D2 Receptor Antagonists : Intravenous haloperidol (2.5 to 5 mg IV/IM) or droperidol (1.25 to 2.5 mg IV/IM) provides rapid, superior relief of nausea and visceral pain compared with conventional antiemetics by acting on central chemoreceptor trigger zone dopamine receptors and modulating hypothalamic signaling. Obtain baseline ECG if prolonged QTc is suspected.

Fluid Resuscitation : Aggressive IV crystalloid rehydration and electrolyte replacement.

Definitive Treatment : The only definitive cure is complete and permanent cessation of all cannabinoid products . Symptoms typically recur within weeks if cannabis use resumes, while full resolution occurs within 1 to 3 months of complete abstinence.

Cognitive, Psychiatric & Cardiovascular Adverse Effects of Cannabis

Neurocognitive Impairment : Acute intoxication impairs working memory, attention, reaction time, and psychomotor coordination (substantially elevating motor vehicle collision risk). Heavy, adolescent-onset chronic use is associated with persistent neurodevelopmental alterations and long-term declines in executive function and IQ.

Psychiatric Complications & Psychosis Risk : High-potency cannabis use is an established, dose-dependent risk factor for the premature onset and exacerbation of chronic psychotic disorders (e.g., schizophrenia) in genetically vulnerable individuals (such as those harboring the catechol-O-methyltransferase [ COMT ] Val158Met polymorphism or AKT1 risk variants). It can also precipitate acute toxic panic attacks and destabilize bipolar disorder.

Cardiovascular Adverse Effects : Cannabis inhalation stimulates sympathetic outflow while inhibiting parasympathetic tone, inducing immediate sinus tachycardia (heart rate increases by 20% to 50%), increased myocardial oxygen consumption, and peripheral vasodilatation leading to orthostatic hypotension. Ingestion or smoking of cannabis is associated with an elevated risk of acute myocardial infarction (especially within 1 hour of use), transient ischemic attack, ischemic stroke, and malignant arrhythmias (atrial fibrillation, ventricular tachycardia) even in young patients without pre-existing coronary artery disease.

Stimulant Use Disorders: Cocaine & Methamphetamine

Psychostimulants are among the most devastating substances encountered in ambulatory and acute care, characterized by rapid neurochemical reinforcement, severe physical toxicity, and intense psychological dependence.

Mechanisms of Action

Cocaine : A tropane alkaloid derived from Erythroxylum coca . Acts as a competitive inhibitor of presynaptic monoamine reuptake transporters—predominantly the Dopamine Transporter (DAT) , Norepinephrine Transporter (NET), and Serotonin Transporter (SERT). In addition, cocaine acts as a local anesthetic by blocking voltage-gated cardiac sodium channels , causing QRS prolongation and pro-arrhythmic potential.

Methamphetamine : A synthetic phenethylamine that acts not only by inhibiting DAT, NET, and SERT, but also by entering presynaptic nerve terminals via DAT and the Vesicular Monoamine Transporter-2 (VMAT-2) . Methamphetamine collapses vesicular proton gradients, causing massive reverse-transport dumping of dopamine and norepinephrine directly into the synaptic cleft. Its elimination half-life is substantially longer (10 to 12 hours) compared to cocaine (60 to 90 minutes), producing prolonged neurotoxicity.

Cardiovascular Complications of Stimulants

Severe Hypertension & Tachycardia : Driven by massive peripheral alpha-1 and beta-1 adrenergic stimulation.

Acute Coronary Vasospasm & Myocardial Infarction : Intense alpha-adrenergic coronary vasoconstriction combined with increased myocardial oxygen demand, platelet hyper-reactivity, and in situ thrombus formation. Occurs even in young individuals with angiographically normal coronary arteries.

Aortic Dissection : Sudden, catastrophic surges in systemic blood pressure ( d P / d t dP/dt d P / d t ) tearing the aortic intima.

Accelerated Coronary Atherosclerosis : Chronic endothelial injury and smooth muscle proliferation.

Stimulant-Induced Dilated Cardiomyopathy : Chronic catecholamine toxicity, microvascular ischemia, and direct toxic myocarditis producing profound left ventricular systolic dysfunction with severely reduced ejection fraction.

Malignant Ventricular Arrhythmias : Triggered by focal ischemia, catecholamine excess, and cocaine's sodium-channel-blocking properties.

Board Exam Pearl: Management of Cocaine-Associated Chest Pain

First-Line Pharmacotherapy : Intravenous benzodiazepines (lorazepam 1–2 mg or diazepam 5–10 mg IV) are the cornerstone of management. Benzodiazepines blunt central sympathetic outflow, reducing heart rate, blood pressure, myocardial oxygen demand, and anxiety.

Coronary Vasospasm Relief : Sublingual or intravenous nitroglycerin and oral or IV calcium channel blockers (diltiazem) are first-line vasodilators to reverse coronary vasoconstriction and lower systemic vascular resistance.

The Beta-Blocker Contraindication : The administration of pure, non-selective beta-blockers (e.g., propranolol) is traditionally contraindicated in acute cocaine intoxication because blocking vasodilatory beta-2 receptors allows unopposed alpha-1 adrenergic vasoconstriction , which can precipitate paradoxical malignant hypertension, severe coronary vasospasm, and acute cardiovascular collapse. While combined alpha/beta-blockers (such as labetalol) have been utilized in selected hypertensive settings, guidelines maintain that benzodiazepines, nitrates, and calcium channel blockers remain the primary evidence-based therapies.

Dental Pathology: "Meth Mouth"

Chronic methamphetamine use causes rampant, devastating oral destruction known as "meth mouth":

Clinical Appearance : Extensive, blackened, crumbling coronal and cervical caries, severe enamel erosion, retained root tips, and advanced periodontal disease, predominantly affecting the buccal smooth surfaces and interproximal anterior teeth.

Multifactorial Etiology :

Severe Xerostomia : Alpha-2 adrenergic stimulation induces microvascular vasoconstriction in salivary glands, severely suppressing salivary flow. Saliva is essential for buffering oral acids and remineralizing enamel.

Intense Bruxism and Clenching : Central dopaminergic and noradrenergic hyperstimulation produces severe trismus, jaw grinding, and structural enamel fractures.

High-Sugar, Acidic Beverage Consumption : Due to extreme dry mouth and cravings for quick calories, users frequently consume large quantities of carbonated, high-sugar, acidic soft drinks.

Severe Oral Hygiene Neglect : Extended periods of intoxication and acute paranoia lead to total abandonment of tooth brushing and dental care.

Neuropsychiatric & Dermatologic Complications

Formication ("Meth Bugs" or "Speed Bumps") : Vivid tactile hallucinations of insects crawling under or on the skin. Users engage in compulsive, excoriating skin picking, resulting in scattered crusted ulcerations, scarred lesions, and secondary bacterial infections (cellulitis, Staphylococcus aureus , MRSA skin abscesses).

Stimulant Psychosis : Persecutory paranoid delusions, hypervigilance, and auditory/visual hallucinations closely mimicking acute paranoid schizophrenia.

The Stimulant "Crash" : Following binges, presynaptic monoamine stores are profoundly depleted, triggering profound dysphoria, anhedonia, severe fatigue, hypersomnia, hyperphagia, and high acute suicide risk .

Treatment of Stimulant Use Disorders : There are currently no FDA-approved medications for cocaine or methamphetamine use disorder. Contingency Management (CM) —an operant conditioning behavioral intervention providing tangible vouchers or prizes for objectively verified negative drug screens—holds the strongest evidence base. In the ADAPT-2 trial, the off-label combination of oral bupropion XL (450 mg/day) plus extended-release injectable naltrexone (380 mg IM every 3 weeks) demonstrated modest efficacy in reducing methamphetamine use in moderate-to-severe users.

Harm Reduction Principles & Essential Primary Care Interventions

Harm reduction is an evidence-based, compassionate public health approach aimed at reducing the adverse health, social, and economic consequences of substance use without demanding immediate abstinence as a mandatory condition of medical care. Primary care physicians have an ethical and clinical obligation to integrate harm reduction into everyday practice.

1. Universal Naloxone Coprescribing

Naloxone is a pure, competitive opioid receptor antagonist that rapidly reverses life-threatening opioid-induced respiratory depression:

CDC Indications for Coprescribing Naloxone :

Any history of non-fatal opioid overdose.

Established diagnosis of Opioid Use Disorder (OUD).

Patients receiving high-dose prescription opioid therapy ( ≥ 50 Morphine Milligram Equivalents [MME]/day \ge 50\text{ Morphine Milligram Equivalents [MME]/day} ≥ 50 Morphine Milligram Equivalents [MME]/day ).

Concurrent prescription or non-medical use of benzodiazepines or other sedatives with opioids.

Co-occurring substance use disorders (e.g., cocaine or methamphetamine users at risk of unintended fentanyl contamination).

Patients with chronic kidney disease, hepatic cirrhosis, COPD, or sleep apnea receiving opioid therapy.

Formulation & Administration : Naloxone nasal spray (4 mg/0.1 mL) administered as a single spray into one nostril. If the patient does not respond within 2 to 3 minutes, administer a second spray into the opposite nostril.

Counseling Pearls : Educate patients, family members, and close contacts on recognizing overdose signs (unresponsiveness, pinpoint pupils, agonal breathing/apnea, cyanosis). Emphasize calling 911 immediately, administering naloxone, performing rescue breathing, and placing the individual in the recovery position. Reassure families that naloxone has zero abuse potential and causes no harm if given to someone not experiencing an opioid overdose.

Recrudescent Toxicity Warning : The half-life of naloxone is relatively short (30 to 90 minutes). Many synthetic opioids (fentanyl analogs, methadone, extended-release formulations) have substantially longer durations of action. Patients may re-sedate and slip back into respiratory arrest once naloxone wears off, mandating emergency department evaluation.

2. Fentanyl Test Strips (FTS)

Rationale : Illicit drug supplies in North America are heavily adulterated with illicitly manufactured synthetic fentanyl and novel analogs. Fentanyl contamination is now routinely detected not only in counterfeit prescription pills (fake "M30" oxycodone, fake Xanax) but also in non-opioid street drugs, including powder cocaine, crack cocaine, and methamphetamine.

Counseling : Fentanyl test strips are low-cost, highly sensitive lateral-flow chromatographic immunoassays. Instruct patients to dissolve a tiny amount of substance residue (e.g., 10 mg) in water, immerse the strip for 15 seconds, and read results at 2 minutes (one line indicates fentanyl present; two lines indicate negative). Educate patients that a negative test does not guarantee safety, as novel non-fentanyl synthetic opioids (such as nitazenes) may not trigger the assay.

3. Syringe Service Programs (SSPs)

Clinical Evidence : SSPs provide access to sterile syringes, needles, injection equipment (cookers, sterile water, cotton filters, alcohol swabs), and safe sharps disposal containers. Extensive epidemiological data confirms that SSPs reduce hepatitis C virus (HCV) and HIV transmission by over 50% without increasing community crime or drug consumption rates.

Complication Prevention : Eliminating equipment reuse and syringe sharing directly prevents life-threatening bacterial infections, including Staphylococcus aureus tricuspid valve endocarditis, vertebral osteomyelitis, spinal epidural abscesses, and necrotizing fasciitis.

Gateway to Recovery : Patients engaged with SSPs are five times more likely to enter substance use treatment and three times more likely to achieve sustained cessation of injection drug use compared to non-participants, serving as a non-judgmental portal into primary care and Medication for Opioid Use Disorder (MOUD with buprenorphine or methadone).

4. Destigmatizing Language in Clinical Documentation

Language directly shapes clinical care and patient engagement. Family physicians should model person-first, medically accurate terminology:

Stigmatizing / Outdated Language Recommended Person-First Medical Language Clinical Rationale

"Addict", "Junkie", "Drug abuser" Person with a substance use disorder Defines the person by their medical condition rather than reducing identity to an illness

"Clean urine" / "Dirty urine" Negative / Positive toxicology screen Eliminates moralistic connotations of purity and dirtiness

"Failed drug screen" Toxicology screen showed expected/unexpected metabolites Removes punitive framing; treats lab data as objective clinical findings

"Relapse" Recurrence of symptoms / Return to use Frames substance use disorder as a chronic relapsing medical disease

"Non-compliant" Experiencing barriers to treatment adherence Prompts investigation into underlying structural and psychological obstacles

Loading diagram... Primary Care Illicit Substance Assessment, CHS Management & Harm Reduction Algorithm